Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Anthoney, D A ^a   Naik, Jay ^a   MacPherson, Iain R J ^b   Crawford, Donna ^b   Hartley, John M ^c   Hartley, Janet A ^c   Saito, Tomohisa ^d   Abe, Masaichi ^d   Jones, Keith ^e   Miwa, Masanori ^d   Twelves, Christopher ^a   Evans, T R J ^b  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^e Chugai Pharmaceuticals Europe Ltd Turnham Green   (United Kingdom)

Author keywords

Pharmacodynamics; Pharmacogenomics; Pharmacokinetics; Phase I study; Safety profile; Topoisomerase I inhibitor

Indexed keywords

ALDEHYDE OXIDASE; ALDEHYDE OXIDASE 1; ANTINEOPLASTIC AGENT; CYTOCHROME P450 2D6; CYTOSINE; DRUG METABOLITE; FIRTECAN; GLUCURONOSYLTRANSFERASE 1A1; GLYCINE,GLYCYL N METHYL, 9 ETHYL 9,10,13,15 TETRAHYDRO 10,13 DIOXO 1 PENTYL 1H,12H PYRANO[3'4':6',7']INDOLIZINO[2',1':5,6]PYRIDO[4,3,2 DE]QUINAZOLIN 9 YL ESTER; GUANINE; IRINOTECAN; TP 300; TP 3011; TP 3076; UNCLASSIFIED DRUG; AOX1 PROTEIN, HUMAN; DIPEPTIDE; DNA TOPOISOMERASE INHIBITOR; FUSED HETEROCYCLIC RINGS; GLUCURONOSYLTRANSFERASE; PRODRUG; UGT1A1 ENZYME;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AOX1 GENE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CYP2D6 GENE; DIARRHEA; DNA STRAND BREAKAGE; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; GASTROENTERITIS; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC POLYMORPHISM; HEPATORENAL SYNDROME; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KIDNEY FUNCTION; LETHARGY; LEUKOPENIA; LIVER FUNCTION; MALE; MALIGNANT ASCITES; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONEUM METASTASIS; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; SEPSIS; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UGT1A1 GENE; URINARY EXCRETION; VISCERAL METASTASIS; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; DNA DAMAGE; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASMS; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; ALDEHYDE OXIDASE; AREA UNDER CURVE; CYTOCHROME P-450 CYP2D6; DIPEPTIDES; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCURONOSYLTRANSFERASE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MOLECULAR STRUCTURE; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRODRUGS; THROMBOCYTOPENIA; TOPOISOMERASE I INHIBITORS; TREATMENT OUTCOME;

EID: 84869210273     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-536     Document Type: Article

References (19)

1. Beretta GL, Perego P, Zunino F. Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors. Expert Opin Ther Targets 2008, 12(10):1243-1256. 10.1517/14728222.12.10.1243, 18781823.
2. United States Food and Drug Administration Camptosar label http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020571s024,027,028lbl.pdf, United States Food and Drug Administration.
3. Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu-Boue A, Verweij J. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995, 6(2):129-132.
4. Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsene D, Paitel JF, Guerin-Meyer V, Mitry E, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 98. J Clin Oncol 2004, 22(21):4319-4328. 10.1200/JCO.2004.01.140, 15514373.
5. Langer CJ. The global role of irinotecan in the treatment of lung cancer: 2003 update. Oncology (Williston Park) 2003, 17(7 Suppl 7):30-40.
6. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 2009, 11(1):80-91. 2718962, 18784279.
7. United States Food and Drug Administration Invader UGT1A1 molecular assay 510(k) summary http://www.accessdata.fda.gov/cdrh_docs/pdf5/K051824.pdf, United States Food and Drug Administration.
8. Endo M, Miwa M, Ura M, Tanimura H, Taniguchi K, Miyazaki Y, Ohwada J, Tsukazaki M, Niizuma S, Murata T, et al. A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts. Cancer Chemother Pharmacol 2010, 65:363-371. 10.1007/s00280-009-1042-5, 19495753.
9. Kamei T, Uchimura T, Nishimiya K, Kawanishi T. Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC-MS/MS, and its application in a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 30:3415-3422.
10. Niizuma S, Tsukazaki M, Suda H, Murata T, Ohwada J, Ozawa S, Fukuda H, Murasaki C, Kohchi M, Morikami K, et al. Synthesis of new camptothecin analogs with improved antitumor activities. Bioorg Med Chem Lett 2009, 19(7):2018-2021. 10.1016/j.bmcl.2009.02.031, 19254843.
11. Hartley JM, Spanswick VJ, Hartley JA. Measurement of DNA damage in individual cells using the single cell gel electrophoresis (comet) assay. Methods Mol Biol 2011, 731:309-320. 10.1007/978-1-61779-080-5_25, 21516417.
12. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: Pharmacogenetics. BMJ 2000, 320(7240):987-990. 10.1136/bmj.320.7240.987, 1117913, 10753155.
13. Shimoda K, Morita S, Hirokane G, Yokono A, Someya T, Takahashi S. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. Pharmacol Toxicol 2000, 86(6):245-249. 10.1111/j.0901-9928.2000.860601.x, 10895986.
14. Hecht JR. Gastrointestinal toxicity or irinotecan. Oncology (Williston Park) 1998, 12(8 Suppl 6):72-78.
15. Dodds HM, Rivory LP. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol 1999, 56(6):1346-1353.
16. Dodds HM, Hanrahan J, Rivory LR. The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables. Anticancer Drug Des 2001, 16:239-246.
17. Smith MA, Marinaki AM, Arenas M, Shobowale-Bakre M, Lewis CM, Ansari A, Duley J, Sanderson JD. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther 2009, 30(4):375-384. 10.1111/j.1365-2036.2009.04057.x, 19500084.
18. Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, et al. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 2000, 6(6):2236-2244.
19. Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, Margison GP, McGown G, Thorncroft M, Watson AJ, et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 2005, 11(9):3402-3409. 10.1158/1078-0432.CCR-04-2353, 15867241.